Glycan-modified nucleic acids, methods of preparation, and therapeutic uses

drug discovery

Fantastic chemistry making glyconucleic acids, such as glycoRNA and glycoDNA using the now world-famous click chemistry to treat diseases such as inflammation disorder, an autoimmune disease, cancer, metabolic disease, clotting disease, anti-clotting disease, allergy, viral disease, and microbial infection.
Ryan Flynn; Ciaran Lawlor; Namita Bisaria, Ph.D.; Richard Cummings; Carolyn Bertozzi et al

See the full patent on Espacenet.

Synthetic biomarkers for differential serological diagnosis of Cutaneous Leishmaniasis (CL) caused by various Leishmania species

carbohydrates, ,

Great patent on neoglycoconjugates and/or glycosides containing glycan selected from Galpα1,3Galfβ, Galpα1,6Galpα1,3Galfβ, or Galpα1,3Galfβ1,3Manpα and their use as diagnostic or prognostic biomarkers, vaccines, treating or detecting parasitic diseases, such as cutaneous leishmaniasis are disclosed.
The University of Texas at El Paso – Igor Almeida, Rosa Amelia Maldonado, Alvaro Acosta-Serrano, Susana Portillo et al.

See the full patent on Espacenet

Our advisory board member will give a presentation at the Innovations in encapsulation 2023 event in London

news

Tamas Sohajda is delighted to share his upcoming keynote at the Innovations in encapsulation 2023 event organized by The Formulation Science and Technology group (FSTG) of the Royal Society of Chemistry, Dr. Shashi Rudrangi and Dr. Cuross Bakhtiar, where he will talk about Innovations in cyclodextrin encapsulation and how we see the future of this field at CarboHyde.
This will be held on Thursday, 20th April 2023, at Burlington House, London, United Kingdom.

Dr. Tamás Sohajda, Member of the Scientific Advisory Board, CarboHyde, and Former CEO of CycloLab, Hungary. – Innovations in cyclodextrins encapsulation: possibilities and challenges. (This lecture will cover advancements in cyclodextrin encapsulation of pharmaceutical, nutraceuticals, and cosmetics)

See the program details here.

Treatment of cancer

carbohydrates, , , ,

This patent on CRLX-101, an experimental approach using camptothecin (CPT) to cancer chemotherapy, reminded us of a wonderful idea from Mark Davis (Caltech). In CRLX101, CPT is linked covalently through a glycine link to the linear copolymer CDP, which in turn consists of alternating subunits of beta-cyclodextrin and polyethylene glycol (PEG). The CRLX101 nanoparticle is water-soluble. After intravenous injection, active CPT is slowly released as the linkage is hydrolyzed. The size of the nanoparticle (20-50 nm in diameter) facilitates its extravasation in the more leaky vessels of tumors via the enhanced permeability and retention effect. As a result, the anticancer drug is enhanced and retained in the tumor tissue.
The new patent from Ellipses Pharma proposes novel applications dominantly in rectal cancer.
Amato Giaccia, Hanna Sanoff, Joel Tepper

Voriconazole Eye Drops: Enhanced Solubility and Stability through Ternary Voriconazole/Sulfobutyl Ether β-Cyclodextrin/Polyvinyl Alcohol Complexes

drug delivery, Today's cyclodextrin, ,

This is a wonderful example of how something known (voriconazole-CD formulation) could be turned into something innovative. Researchers from Chulalongkorn University and Iceland University developed voriconazole eyedrops which shows high mucoadhesion, sustained release, good ex vivo permeability through the porcine cornea, and no sign of irritation. The stability study revealed that VCZ eye drops provide a shelf-life of more than 2.5 years at room temperature, while a shelf-life of only 3.5 months was observed for the extemporaneous Vfend® eye drops.

Hay Man Saung Hnin Soe, Khanittha Kerdpol, Thorsteinn Loftsson Phatsawee Jansook et al

Targeting bacterial virulence as a novel treatment against AMR infections

drug development, ,

Have you known that Arivin Therapeutics uses cyclodextrin for targeting bacterial virulence as a novel treatment against AMR infections? Among their MoA claims, the following are listed:
– Targeting virulence factors is effective, also against extensively resistant isolates
– Targeting virulence avoids rapid resistance
– Direct reduction in inflammatory responses
– Potentiates the function of antibiotics
Also, there is a spectacular video about how CDs develop their effect as antibacterials.

https://arivintx.com/our-science

Incorporation of Hydrophilic Macrocycles Into Drug-Linker Reagents Produces Antibody-Drug Conjugates With Enhanced in vivo Performance

Today's cyclodextrin, ,

Antibody-drug conjugates (ADCs) have begun to fulfill their promise as targeted cancer therapeutics with ten clinical approvals to date. Recently the role that linker-payload reagent design has on the properties of ADCs has been highlighted as an important consideration for developers. In this paper from Abzena, the effect of incorporating hydrophilic macrocycles like cyclodextrin into reagent structures on the in vitro and in vivo behavior of ADCs.

Nick Evans, Ruslan Grygorash, Nicolas Camper, Mark Frigerio, Matthew Bird et al

See the full article here

Disease management to disease modification – removing plaque to undo atherosclerosis

Today's cyclodextrin, ,

You can read a great interview with folks from Cyclarity Therapeutics at Longevity.Technology. Since they are one of the few companies developing tailor-made CDs to tackle a major disease, this is certainly worth attention.
“Cyclarity’s approach to true disease medication, and therefore reversal of age-related disease, without doubt, offers a great deal of promise for investors, for healthcare systems in the US and globally, and most of all for those affected by the atherosclerosis-related disease.
. . . this may be the perfect opportunity for Cyclarity to enter the field, as it is one of the few solutions available that addresses the limiting factors of previous therapies both from a scientific perspective and from a market perspective.”

See the full article here